The FDA's ongoing review of mifepristone could skip over established science, health experts warn

The reported study could allow the Trump administration to limit the distribution of the abortion pill by mail or telehealth services.

The full results are unlikely to be completed before November's midterm elections, the report said.

The FDA's ongoing review of mifepristone could skip over established science, health experts warn